DISCUSSION
infection, death, SARS-CoV-2 infection
INFECTION, DISEASE, SARS-COV-2 INFECTION
This analysis of clinical trial data from CSSC-004, investigating the impact of CCP for the treatment of COVID-19 on resolution of symptoms, has several important findings. In both the CCP and control treatment arms, 70% of participants still experienced COVID-19 symptoms at day 14. There was no statistically significant difference in the time to resolution of all symptoms by day 14 between CCP and control plasma. After clustering symptoms both on clinical significance and algorithmically, based on how they presented in the CSSC-004 study population, there were no significant differences in the prevalence of symptoms between treatment groups at day 14. Finally, looking at the prevalence of individual symptoms and the prevalence of any symptom at day 14, there were no significant differences between treatment groups.As expected, the severity of symptoms decreased with time, even for those with the most advanced symptoms. Consistent with findings of other studies [Our results contribute to existing data on symptom resolution with the use of antibodies [Therapy with monoclonal antibodies and CCP has been shown to reduce hospitalization and death rates when used early in the course of SARS-CoV-2 infection [This study had several notable strengths. First, the CSSC-004 study population was large and outpatient at enrollment, and the study was double masked. Second, high-titer CCP was used, in line with the current US Food and Drug Admsinistration's emergency use authorization [Our analyses had limitations. First, the k-means cluster analysis enabled us to group symptoms based on their prevalence over the course of the disease. However, the biologic plausibility of the relationships within these symptom groupings was difficult to ascertain. This was possibly affected by the addition of symptoms to the data collection instruments as the clinical definition of COVID-19 evolved. Owing to masking of participants, differential reporting of symptoms is unlikely. Second, this study was conducted early in the pandemic, when relatively few participants were fully vaccinated. Results may differ for patients who have immunity from prior infection or vaccination. Finally, while we did not identify statistically significant differences in treatment effect between participants presenting in the Alpha and Delta waves, it is undetermined whether this will remain true for subsequent variants of concern.As rates of hospitalizations and death after infection with SARS-CoV-2 have decreased, the focus has shifted, and new treatment trials are using symptom resolution as their outcome [